Pfizer/Eisai Aricept meeting canceled
The May 16 meeting of FDA's Peripheral & Central Nervous System Drugs Advisory Committee to review Pfizer/Eisai's Aricept for vascular dementia has been cancelled by the agency...
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.